Effect of CCK antagonists in Obstructive Sleep Apnea (OSA) syndrome. A randomized, double-blind, cross-over study
Latest Information Update: 04 Apr 2016
Price :
$35 *
At a glance
- Drugs Dexloxiglumide (Primary) ; Itriglumide (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Rotta Pharmaceuticals
- 02 Apr 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 10 Feb 2014 New trial record